問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of General Surgery

Division of Hematology & Oncology

Division of Gastroenterological Surgery

更新時間：2024-06-04

侯明鋒Hou, Ming-Feng
  • Principal Investigator
  • Clinical Trial Experience (year) 24 years

Recruiting Trial

27Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

侯明鋒

List

78Cases

2018-11-30 - 2023-06-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting5Sites

Terminated1Sites

2023-01-31 - 2032-12-03

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2014-07-01 - 2028-12-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2022-01-10 - 2028-12-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2017-02-01 - 2027-02-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated5Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

侯明鋒
Kaohsiung Municipal Gangshan Hospital

未分科

2024-03-01 - 2030-09-20

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2007-04-01 - 2020-04-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2008-12-20 - 2010-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2016-06-01 - 2021-12-24

Phase III

A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF TASELISIB PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE AND HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE DISEASE RECURRENCE OR PROGRESSION DURING OR AFTER AROMATASE INHIBITOR THERAPY

  • Condition/Disease

    LOCALLY ADVANCED OR METASTATIC BREAST CANCER

  • Test Drug

    TASELISIB and FULVESTRANT

Participate Sites
9Sites

Terminated7Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2016-09-01 - 2020-11-09

Phase II

A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY.

  • Condition/Disease

    HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

  • Test Drug

    KADCYLA

Participate Sites
10Sites

Terminated8Sites

侯明鋒
Kaohsiung Municipal Gangshan Hospital

未分科

曾令民
Taipei Veterans General Hospital

Division of General Surgery

1 3 4 5 6 7 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB